165 related articles for article (PubMed ID: 35122586)
1. Circulating tumor cells may serve as a supplement to RECIST in neoadjuvant chemotherapy of patients with locally advanced breast cancer.
Wang J; Wang X; Chen R; Liang M; Li M; Ma G; Xia T; Wang S
Int J Clin Oncol; 2022 May; 27(5):889-898. PubMed ID: 35122586
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer.
Ma G; Wang J; Fu J; Chen R; Liang M; Li M; Xia T; Liu X; Wang S
Breast Cancer Res Treat; 2023 Aug; 201(1):27-41. PubMed ID: 37311933
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
Bidard FC; Michiels S; Riethdorf S; Mueller V; Esserman LJ; Lucci A; Naume B; Horiguchi J; Gisbert-Criado R; Sleijfer S; Toi M; Garcia-Saenz JA; Hartkopf A; Generali D; Rothé F; Smerage J; Muinelo-Romay L; Stebbing J; Viens P; Magbanua MJM; Hall CS; Engebraaten O; Takata D; Vidal-Martínez J; Onstenk W; Fujisawa N; Diaz-Rubio E; Taran FA; Cappelletti MR; Ignatiadis M; Proudhon C; Wolf DM; Bauldry JB; Borgen E; Nagaoka R; Carañana V; Kraan J; Maestro M; Brucker SY; Weber K; Reyal F; Amara D; Karhade MG; Mathiesen RR; Tokiniwa H; Llombart-Cussac A; Meddis A; Blanche P; d'Hollander K; Cottu P; Park JW; Loibl S; Latouche A; Pierga JY; Pantel K
J Natl Cancer Inst; 2018 Jun; 110(6):560-567. PubMed ID: 29659933
[TBL] [Abstract][Full Text] [Related]
4. Are changes in circulating tumor cell (CTC) count associated with the response to neoadjuvant chemotherapy in local advanced breast cancer? A meta-analysis.
Fei F; Du Y; Di G; Wu J; Shao Z
Oncol Res Treat; 2014; 37(5):250-4. PubMed ID: 24853784
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
Gwark S; Kim J; Kwon NJ; Kim KY; Kim Y; Lee CH; Kim YH; Kim MS; Hong SW; Choi MY; Jeon BH; Chang S; Yu J; Park JY; Lee HJ; Lee SB; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn JH; Jung KH; Kim SB; Gong GY; Ahn SH
Sci Rep; 2020 Oct; 10(1):17466. PubMed ID: 33060768
[TBL] [Abstract][Full Text] [Related]
6. Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.
Ma G; Wang J; Huang H; Han X; Xu J; Veeramootoo JS; Xia T; Wang S
Cancer Med; 2020 Apr; 9(7):2271-2282. PubMed ID: 32017472
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer.
Ni C; Shen Y; Fang Q; Zhang M; Yuan H; Zhang J; Zhong M; Zheng Y
Cancer Med; 2020 Apr; 9(7):2290-2298. PubMed ID: 32017443
[TBL] [Abstract][Full Text] [Related]
8. DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Li XR; Cheng LQ; Liu M; Zhang YJ; Wang JD; Zhang AL; Song X; Li J; Zheng YQ; Liu L
Med Oncol; 2012 Jun; 29(2):425-31. PubMed ID: 21286861
[TBL] [Abstract][Full Text] [Related]
9. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Bidard FC; Mathiot C; Delaloge S; Brain E; Giachetti S; de Cremoux P; Marty M; Pierga JY
Ann Oncol; 2010 Apr; 21(4):729-733. PubMed ID: 19850639
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumour cells in locally advanced breast cancer.
García-Sáenz JA; Martín M; Maestro ML; Vidaurreta M; Veganzones S; Rafael S; Casado A; Bobokova J; Sastre J; De la Orden V; Arroyo M; Díaz-Rubio E
Clin Transl Oncol; 2009 Aug; 11(8):544-7. PubMed ID: 19661030
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of Circulating Tumor Cells for Evaluating Short- and Long-Term Efficacy of Chemotherapy for Breast Cancer.
Ma S; Ling F; Gui A; Chen S; Sun Y; Li Z
Med Sci Monit; 2017 Oct; 23():4808-4816. PubMed ID: 28986517
[TBL] [Abstract][Full Text] [Related]
12. Dynamic monitoring of CD45-/CD31+/DAPI+ circulating endothelial cells aneuploid for chromosome 8 during neoadjuvant chemotherapy in locally advanced breast cancer.
Ma G; Jiang Y; Liang M; Li J; Wang J; Mao X; Veeramootoo JS; Xia T; Liu X; Wang S
Ther Adv Med Oncol; 2020; 12():1758835920918470. PubMed ID: 32489429
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Carcinoma Using Image-Guided Clip Placement.
Pandurangappa V; Paruthy SB; Jamwal R; Singh A; Tanwar S; Kumar D; Pal S; Mohan SK; Das A; Trs PR
Cureus; 2023 Oct; 15(10):e47763. PubMed ID: 38021852
[TBL] [Abstract][Full Text] [Related]
14. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.
Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M
Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695
[TBL] [Abstract][Full Text] [Related]
15. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
16. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status.
Vilsmaier T; Heidegger HH; Schröder L; Trapp E; Zehni AZ; Rack B; Janni W; Mahner S; Weissenbacher T; Jeschke U; Mumm JN;
Arch Gynecol Obstet; 2021 Jan; 303(1):217-230. PubMed ID: 32929618
[TBL] [Abstract][Full Text] [Related]
18. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
Ma B; King AD; Leung L; Wang K; Poon A; Ho WM; Mo F; Chan CML; Chan ATC; Wong SCC
Ann Oncol; 2017 Jul; 28(7):1576-1581. PubMed ID: 28379285
[TBL] [Abstract][Full Text] [Related]
19. RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.
Massard C; Borget I; Farace F; Aspeslagh S; Le Deley MC; Le Tourneau C; Bidard FC; Pierga JY; Dieras V; Hofman P; Spano JP; Ferte C; Lacroix L; Soria JC
Eur J Cancer; 2017 Sep; 83():185-193. PubMed ID: 28743036
[TBL] [Abstract][Full Text] [Related]
20. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
Akkiprik M; Koca S; Uğurlu MÜ; Ekren R; Peker Eyüboğlu İ; Alan Ö; Erzik C; Güllü Amuran G; Telli TA; Güllüoğlu MB; Sezerman U; Yumuk PF
Clin Breast Cancer; 2020 Aug; 20(4):332-343.e3. PubMed ID: 32201164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
